• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

    8/3/23 9:05:00 AM ET
    $MEDS
    Other Pharmaceuticals
    Health Care
    Get the next $MEDS alert in real time by email
    • Forbes Fisher Appointed as Chief Operating Officer.
    • Dr. Eugenio Bortone Appointed as Chief Innovation & Food Technology Officer.

    TAMPA, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc (NASDAQ:MEDS), parent company of pharmaceutical B2B exchange platform, which recently merged with Superlatus, Inc today announced the appointments of Forbes Fisher as Chief Operating Officer and Dr. Eugenio (Gino) Bortone as Chief Innovation & Food Technology Officer. Forbes brings over 25 years of Food Services industry experience and will lead product innovation and information technology, and drive sales and supply chain optimization to support growth and profitability initiatives. Dr. Eugenio Bortone, one of the world's most preeminent food scientists, extrusion processing experts, and inventor of Frito-Lay's Twisted Cheetos.

    "We are most excited to welcome Forbes and Dr. Gino to Superlatus management team, as their respective skillsets comprise of consumer product group (CPG) and consumer industry expertise across food innovation, vertical integration and operational functions," said Tim Alford, Interim Chief Executive Officer of Superlatus, Inc. "As we continue transforming the organization, their leadership will be critical to scaling our business, driving growth, profitability and value creation."

    "I am excited to join Superlatus and the impressive management team as the company continues to execute its long-term growth plan. I look forward to helping the team deliver growth and accelerate profitability, while meeting increasing consumer demand for a product that is plant based and environmentally friendly. I am proud to contribute to a company where improving people's lives and the environment is at the forefront of every business decision'," said Forbes 

    "I am proud to be part of a company that not only has a clear vision for growth by enhancing the vertical integrated plant-based protein market from ‘farm to fork, but also is driven by a mission to support the health of individuals and communities," said Dr. Bortone.

    Forbes Fisher - Chief Operating Officer

    Mr. Fisher is a 15-year veteran of the consumer-packaged goods, food, and beverage industry, and has served in a variety of leadership roles in manufacturing, engineering, supply chain strategy and planning, human resources, and enterprise shared services. Most recently, he served as COO of MOKU Foods, where he led a capacity and capability expansion program and operational improvements that enabled MOKU to substantially increase in size and become one of the fastest growing plant-based jerky in the world. From 2016 to 2019, he served as CEO of Canopy Food which encompassed both Manufacturing and Supply Chain Strategy. Forbes attended Columbia University, where he studied Philosophy and Environmental Science.

    Dr. Eugenio Bortone – President and CTO

    Dr. Bortone has successfully created new-to-the-world innovation for new products and new technologies. He has held several positions in PepsiCo that included Sr. Global Technical Extrusion Leader, and Senior Scientist for the Global Nutrition Group. During his tenure in PepsiCo, he developed and launched several multimillion-dollar products such as Twisted Cheetos, which brought the Cheetos Brand for the first time to a Billion dollars in sales. At the end of his career in Frito Lay North America he had 20 authored patents. For his creativity, in 2004 he was recognized by PepsiCo with the Worldwide Creative Award, Chairman's Award, and in 2010 was the first recipient of the Thomas Edison Award. In 2017, he applied for 7 patents, and in December 2018 the USPTO awarded the first 3. Gino is a Certified Food Scientist, and has a Ph.D. in Grain Science, a MS in Nutrition, and a BS all from Kansas State University.

    About Superlatus, Inc.

    Superlatus is a diversified food technology company with distribution capabilities. We scale food innovation and transformational change to our food systems to optimize food security and population health via innovative CPG products, agritech, foodtech, plant-based proteins and alt-proteins. We provide industry-leading processing and forming technologies that create high nutrition, high taste, and textured foods. Our management team consists of world-class food executives with an unparalleled understanding of technology and taste. For more information on Superlatus, please visit Superlatus' website at https://www.superlatusfoods.com.

    About TRxADE HEALTH, INC.

    TRxADE HEALTH (NASDAQ:MEDS) parent company of pharmaceutical B2B marketplace. The marketplace subsidiary continues to operate as private company (www.trxade.com), serving approximately 14,500+ members nationwide, fostering price transparency.

    For more information on TRxADE HEALTH merger with Superlatus, Inc. https://www.sec.gov/ix?doc=/Archives/edgar/data/1382574/000149315223026024/form8-k.htm

    Forward-Looking Statements

    This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; risks that one or more conditions to closing of the Merger may not be satisfied within the expected timeframe or at all or that the closing of the proposed Merger will not occur; the outcome of any current legal proceedings or future legal proceedings that may be instituted against the parties or others, including proceedings related to the Merger documents; the occurrence of any event, change or other circumstance or condition that could give rise to the termination or abandonment of the Merger; unanticipated difficulties or expenditures relating to the proposed Merger; potential difficulties in employee retention as a result of the announcement and pendency of the proposed Merger; whether the combined business of TRxADE and Superlatus will be successful; and those risks detailed in TRxADE's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. The TRxADE undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

    Investor Contact:

    Skyline Corporate Communications Group, LLC

    Scott Powell, President

    One Rockefeller Plaza, 11th Floor

    New York, NY 10020

    Office: (646) 893-5835

    Email: [email protected]



    Primary Logo

    Get the next $MEDS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MEDS

    DatePrice TargetRatingAnalyst
    12/9/2021$4.50Buy
    EF Hutton
    More analyst ratings

    $MEDS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

      SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

      1/21/25 8:15:00 AM ET
      $MEDS
      $OGEN
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to "SCNX"

      TRxADE Health, Inc. today announced that it changed its name and ticker symbol to "Scienture Holdings, Inc." and "SCNX", respectively, and that the business will continue as a Nasdaq-listed company. TAMPA, FL, Sept. 24, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (the "Company") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of the Company, today announced that the Company has changed its name to "Scienture Holdings, Inc." Effective as of September 23, 2024, the Company's stock is now trading on the Nasdaq Stock Market LLC under the new ticker symbol "SCNX". Scienture Holdings, Inc., through its wholly owned subsidiaries, Scienture and Integra Pharma Solutions

      9/24/24 8:01:00 AM ET
      $MEDS
      $SCNX
      Other Pharmaceuticals
      Health Care
    • TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

      TAMPA, FL and COMMACK, NY, Sept. 20, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. ("TRxADE") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of TRxADE, today announced that it is changing its name to Scienture Holdings, Inc. ("Scienture Holdings"), effective Monday, September 23, 2024. Scienture Holdings stock will begin trading under the new ticker symbol NASDAQ:SCNX on September 23, 2024. About TRxADE TRxADE HEALTH, INC. historically focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience. Our current primary operations are conducted through our wholly-owned subsidiary, Integra Pharma Solutions, LLC ("IPS"), whi

      9/20/24 11:59:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care

    $MEDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Shankar Hariharan claimed ownership of 97,087 shares (SEC Form 3)

      3 - TRxADE HEALTH, INC (0001382574) (Issuer)

      8/5/24 9:23:01 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • New insider Narasimhan Mani claimed ownership of 57,977 shares (SEC Form 3)

      3 - TRxADE HEALTH, INC (0001382574) (Issuer)

      8/5/24 9:23:00 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • Ajjarapu Surendra K was granted 10,000 shares (SEC Form 4) (Amendment)

      4/A - TRxADE HEALTH, INC (0001382574) (Issuer)

      5/28/24 5:01:21 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care

    $MEDS
    Financials

    Live finance-specific insights

    See more
    • TRxADE Health, Inc. Announces Special Cash Dividend

      TAMPA, FL, July 09, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ:MEDS) (the "Company"), announced that the Company's board of directors has declared a special cash dividend of $1.50 per share of common stock. The special dividend is being paid using a portion of the proceeds received in May 2024 in connection with the prior sale of the Company's web-based market platform assets. The special cash dividend is payable to stockholders of record as of July 19, 2024, with the dividend being paid on or about July 24, 2024. Forward-Looking Statements This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, in

      7/9/24 8:05:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • TRxADE Health, Inc. Announces Special Cash Dividend

      TAMPA, FL, March 06, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH Inc. (NASDAQ:MEDS) (the "Company"), announced that the Company's board of directors has declared a special cash dividend of $8.00 per share of common stock. The special dividend is being paid using a portion of the proceeds from the closing of the recently announced sale of the Company's web-based market platform assets. The special cash dividend is payable to stockholders of record as of March 18, 2024, with the dividend being paid on or about March 22, 2024. Forward-Looking Statements This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, includi

      3/6/24 8:05:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

      Spero is another addition to the growing Superlatus CPG portfolio under their Urgent Company umbrella of brands.Spero® is a plant-based tech company specializing in alternative dairy and egg replacements, on a mission to outcompete traditional dairy and egg products in scale, price, taste, and nutrition by utilizing internationally patent-pending technologies that transforms low-cost, sustainable, and scalable ingredients into plant-based alternatives. Spero's mission is to scale mainstream dairy alternatives and have them be delicious, affordable, and available to everyone, everywhere. TAMPA, FL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Superlatus, Inc. ("Superlatus"), wholly owned subsidary of

      10/4/23 8:05:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care

    $MEDS
    Leadership Updates

    Live Leadership Updates

    See more
    • Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

      SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

      1/21/25 8:15:00 AM ET
      $MEDS
      $OGEN
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

      TAMPA, FL and COMMACK, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. ("TRxADE") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of TRxADE, today announced the appointment of Narasimhan Mani, Ph.D., MBA as Scienture's President. Shankar Hariharan, Ph.D., the current President and CEO, will be CEO of Scienture. Rahul Surana, Ph.D., MBA has been promoted to Executive VP and COO of Scienture. Dr. Narasimhan Mani is an experienced healthcare professional and a proven leader with over 25 years of experience in both the scientific and business areas of the pharmaceutical industry. He currently is a part of the Executives-in-Residence program at New Rhein Hea

      8/5/24 8:01:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

      Forbes Fisher Appointed as Chief Operating Officer.Dr. Eugenio Bortone Appointed as Chief Innovation & Food Technology Officer. TAMPA, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc (NASDAQ:MEDS), parent company of pharmaceutical B2B exchange platform, which recently merged with Superlatus, Inc today announced the appointments of Forbes Fisher as Chief Operating Officer and Dr. Eugenio (Gino) Bortone as Chief Innovation & Food Technology Officer. Forbes brings over 25 years of Food Services industry experience and will lead product innovation and information technology, and drive sales and supply chain optimization to support growth and profitability initiatives. Dr. Eugenio

      8/3/23 9:05:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care

    $MEDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EF Hutton initiated coverage on Trxade Health with a new price target

      EF Hutton initiated coverage of Trxade Health with a rating of Buy and set a new price target of $4.50

      12/9/21 9:10:50 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • Maxim Group initiated coverage on Trxade Group

      Maxim Group initiated coverage of Trxade Group with a rating of Buy

      2/26/21 8:08:35 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care

    $MEDS
    SEC Filings

    See more
    • TRxADE HEALTH Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Scienture Holdings, Inc. (0001382574) (Filer)

      9/24/24 4:05:38 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • SEC Form DEF 14C filed by TRxADE HEALTH Inc.

      DEF 14C - TRxADE HEALTH, INC (0001382574) (Filer)

      8/28/24 4:05:30 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • SEC Form PRE 14C filed by TRxADE HEALTH Inc.

      PRE 14C - TRxADE HEALTH, INC (0001382574) (Filer)

      8/15/24 9:57:20 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care

    $MEDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by TRxADE HEALTH Inc. (Amendment)

      SC 13G/A - TRxADE HEALTH, INC (0001382574) (Subject)

      2/14/24 2:50:57 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by TRxADE HEALTH Inc.

      SC 13G - TRxADE HEALTH, INC (0001382574) (Subject)

      2/14/23 1:05:54 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by TRxADE HEALTH Inc. (Amendment)

      SC 13D/A - TRxADE HEALTH, INC (0001382574) (Subject)

      10/19/22 4:30:15 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care